Surgery Partners - SGRY Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surgery Partners in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SGRY shares.
View SGRY analyst ratings or view top-rated stocks.

6 brokers have issued twelve-month price targets for Surgery Partners' stock. Their SGRY share price forecasts range from $36.00 to $73.00. On average, they expect the company's share price to reach $57.44 in the next year. This suggests a possible upside of 145.5% from the stock's current price.
View analysts price targets for SGRY or view top-rated stocks among Wall Street analysts.

Surgery Partners' stock was trading at $53.41 at the beginning of the year. Since then, SGRY stock has decreased by 56.2% and is now trading at $23.40.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 1st 2022.
View our SGRY earnings forecast.

Surgery Partners, Inc. (NASDAQ:SGRY) announced its earnings results on Tuesday, August, 2nd. The company reported ($0.08) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.08). The business had revenue of $615.40 million for the quarter, compared to the consensus estimate of $624.64 million. Surgery Partners had a negative net margin of 1.23% and a negative trailing twelve-month return on equity of 0.61%.

Surgery Partners issued an update on its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.50 billion-$2.60 billion, compared to the consensus revenue estimate of $2.56 billion.

7 employees have rated Surgery Partners Chief Executive Officer Eric Evans on Glassdoor.com. Eric Evans has an approval rating of 86% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Surgery Partners investors own include Sorrento Therapeutics (SRNE), Rigel Pharmaceuticals (RIGL), Ardelyx (ARDX), Glu Mobile (GLUU), Ocular Therapeutix (OCUL), Sangamo Therapeutics (SGMO), Xilinx (XLNX), Allena Pharmaceuticals (ALNA), Editas Medicine (EDIT) and Maxar Technologies (MAXR).

Surgery Partners trades on the NASDAQ under the ticker symbol "SGRY."

Shares of SGRY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SGRY stock can currently be purchased for approximately $23.40.

Surgery Partners (NASDAQ:SGRY) has a market capitalization of $2.10 billion and generates $2.23 billion in revenue each year. The company earns $-70,900,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis.

The company employs 10,900 workers across the globe.

Surgery Partners' mailing address is 310 Seven Springs Way Suite 500, Brentwood TN, 37027. The official website for the company is www.surgerypartners.com. The company can be reached via phone at (615) 234-5900, via email at ir@surgerypartners.com, or via fax at 615-234-5998.